GlassScriptPhysician profile
Kenneth B Johnson
NPI 1063527711
$18,628.03
in general payments reported to CMS, 2019-2025
72 companies · $1,772 in 2025
The $1,772 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,053 · 2020: $1,850 · 2021: $2,801 · 2022: $1,830 · 2023: $1,220 · 2024: $1,102 · 2025: $1,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,541 · Education: $386 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,541.13 |
| Education | $386.31 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $4,700.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $4,137.63 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $832.44 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $611.69 | 2019-2025 | Imfinzi, Calquence |
| Pfizer INC. | $581.42 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $547.38 | 2019-2025 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $435.98 | 2019-2023 | Imbruvica, Epkinly |
| Amgen INC. | $428.94 | 2019-2023 | Kyprolis, Blincyto |
| Janssen Biotech, INC. | $331.03 | 2019-2025 | Erleada, Rybrevant |
| Blueprint Medicines Corporation | $273.88 | 2020-2023 | Ayvakit |
| Astellas Pharma US INC | $268.12 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $263.18 | 2020 | |
| Genentech USA, INC. | $261.23 | 2019-2025 | Polivy, Lunsumio, Columvi |
| Gilead Sciences, INC. | $245.86 | 2019-2025 | Trodelvy |
| Epizyme, INC. | $242.56 | 2020-2021 |
Show all 68 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.